Salicylic acid

Description

The drug is identified by the SPL code 34089-3 and is characterized by its chemical name, physical properties, and inactive ingredients. It is formulated in a specific dosage form and strength, ensuring precise administration. The packaging details and labeling information provide essential guidance for handling and usage. The drug's appearance, including its color and shape, is clearly defined, facilitating identification. Additionally, unique identifiers or codes associated with the drug are included to support traceability and regulatory compliance.

Uses and Indications

This drug is indicated for the removal of warts, including plantar warts, flat warts, common warts, corns, and calluses. Plantar warts are specifically characterized by their location on the bottom of the foot, tenderness upon pressure, and disruption of the normal footprint pattern.

There are no teratogenic or nonteratogenic effects associated with this drug.

Dosage and Administration

The affected area should be washed thoroughly prior to treatment. For optimal results, the wart may be soaked in warm water for approximately 5 minutes. After soaking, the area must be dried completely.

Using an applicator, such as a cotton swab, a layer of ointment should be applied to sufficiently cover each wart. It is important to allow the ointment to fully absorb into the skin. If necessary, the treated area may be covered with a bandage.

This procedure should be repeated once or twice daily as needed, continuing until the wart is removed, for a maximum duration of 12 weeks.

Contraindications

Use of this product is contraindicated in individuals with a known allergy to any of its ingredients. Additionally, it should not be used during pregnancy or breastfeeding due to potential risks to the mother and child.

The product is also contraindicated for application on damaged skin, including cuts, abrasions, eczema, or sunburn, as this may exacerbate irritation or lead to adverse effects.

Warnings and Precautions

The liquid formulation is prone to volatilization and crystallization; therefore, it is imperative to securely tighten the cap after each use to maintain its integrity. Prolonged exposure to air should be avoided to prevent degradation of the product. This formulation is intended for external use only; it must not come into contact with the eyes or be ingested. It is essential that children use this product under adult supervision to ensure safety.

Caution is advised when applying the product to damaged skin, including areas with cuts, abrasions, eczema, or sunburn. Individuals with known allergies to any of the ingredients in this formulation should refrain from use. Additionally, pregnant or breastfeeding individuals should consult a healthcare professional prior to use to assess any potential risks.

No specific laboratory tests have been recommended for monitoring the use of this product. In the event of an adverse reaction or if symptoms worsen, it is crucial to discontinue use and seek medical advice promptly. Emergency medical assistance should be obtained if severe reactions occur.

Side Effects

Patients should be aware of several important warnings associated with the use of this product. The liquid formulation is prone to volatilization and crystallization; therefore, it is essential to tighten the cap securely after each use to maintain its integrity. Long-term exposure to air should be avoided to prevent degradation of the product.

This formulation is intended for external use only. Patients must take care to avoid contact with the eyes and should not ingest the product. Additionally, it is recommended that children use this product only under the supervision of an adult to ensure safety and proper application.

Drug Interactions

No drug interactions or drug and laboratory test interactions have been identified for this product. Therefore, no specific recommendations for dosage adjustments or monitoring are necessary at this time.

Packaging & NDC

Below are the non-prescription pack sizes of Tag Wart Remover. Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients should use this medication under the supervision of adults to ensure safety and proper administration. It is important to keep the medication out of reach of children to prevent accidental ingestion or misuse.

Geriatric Use

There is no specific information regarding the use of this medication in geriatric patients, including dosage adjustments, safety concerns, or special precautions. Healthcare providers should exercise caution when prescribing this medication to elderly patients, as individual responses may vary. Monitoring for potential adverse effects and therapeutic efficacy is recommended in this population.

Pregnancy

Pregnant patients and those who are breastfeeding are advised against the use of this product. The potential risks associated with the use of this product during pregnancy and lactation have not been established, and therefore, it is recommended that women of childbearing potential avoid its use to prevent any adverse fetal outcomes or effects on breastfeeding infants.

Lactation

Lactating mothers should be aware of the potential implications of using this medication while breastfeeding. There is limited information available regarding the excretion of this drug in human breast milk. Therefore, healthcare professionals should carefully consider the benefits and risks of administering this medication to lactating mothers.

Breastfed infants may be affected by the presence of the drug in breast milk, although specific effects on nursing infants have not been established. It is advisable for healthcare providers to monitor breastfed infants for any adverse reactions if the mother is using this medication.

In cases where the medication is deemed necessary, healthcare professionals should counsel lactating mothers on the importance of reporting any unusual symptoms in their infants.

Renal Impairment

There is no specific information available regarding dosage adjustments, special monitoring, or safety considerations for patients with renal impairment. Healthcare professionals should exercise caution when prescribing to patients with reduced kidney function, as the lack of data necessitates careful clinical judgment. Regular monitoring of renal function may be advisable in these patients, although specific recommendations are not provided.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to the use of this medication. Consequently, there are no established dosage adjustments, special monitoring requirements, or precautions outlined for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the available information.

Overdosage

In the absence of specific information regarding overdosage, healthcare professionals are advised to exercise caution and adhere to general principles of management in cases of suspected overdose.

It is essential to monitor the patient closely for any potential symptoms that may arise from an overdose. Symptoms can vary widely depending on the substance involved and the individual patient's response.

In the event of an overdose, immediate medical attention should be sought. Healthcare providers should implement supportive care measures, which may include maintaining airway patency, providing supplemental oxygen, and monitoring vital signs.

Additionally, the use of activated charcoal may be considered if the patient presents within a suitable timeframe and if the ingestion of the substance is confirmed.

For specific management protocols, healthcare professionals should refer to established guidelines and consult poison control centers as necessary.

Nonclinical Toxicology

If pregnancy or breastfeeding is applicable, caution is advised due to potential teratogenic effects. No relevant information is available regarding non-teratogenic effects, nonclinical toxicology, or animal pharmacology and toxicology.

Postmarketing Experience

No postmarketing experience details are available in the insert text.

Patient Counseling

Healthcare providers should advise patients to keep the product out of reach of children to prevent accidental ingestion or misuse.

Patients should be instructed not to use the product on damaged skin, including cuts, abrasions, eczema, or sunburn, as this may exacerbate the condition or lead to adverse effects.

It is important for healthcare providers to inquire about any known allergies to the ingredients in the product. Patients should be informed to discontinue use and consult a healthcare professional if they experience any allergic reactions.

Additionally, healthcare providers should discuss the implications of using the product during pregnancy or while breastfeeding, ensuring that patients understand the potential risks and benefits associated with its use in these circumstances.

Storage and Handling

The product is supplied in various package configurations, with specific NDC numbers available for identification. It is essential to store the product at a temperature range of 68°F to 77°F (20°C to 25°C) to maintain its efficacy. Care should be taken to protect the product from excessive heat, specifically temperatures exceeding 104°F (40°C), to prevent degradation. Proper storage conditions are crucial for ensuring the integrity and quality of the product throughout its shelf life.

Additional Clinical Information

No further data are available.

Drug Information (PDF)

This file contains official product information for Tag Wart Remover, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)